We are excited to report that the Phase 2 Clinical Trial of AMX0035 for the Treatment of Wolfram Syndrome has commenced, with the first participant already dosed earlier this week. This marks our second clinical trial for Wolfram Syndrome, and we are incredibly grateful for the unwavering support from our patients, their families, and the community at large.
Sincerely,
Fumi URANO, MD, PhD
Professor of Medicine @ Washington University